Supervised Exercise Therapy and Adjuvant Chemotherapy for Pancreatic Cancer: A Prospective, Single-Arm, Phase II Open-Label, Nonrandomized, Historically Controlled Study

Authors:

Abstract
Background: Improvement of the completion rate of postoperative adjuvant chemotherapy is a key to obtaining favorable prognosis in patients who undergo macroscopically curative pancreatectomy for pancreatic ductal adenocarcinoma (PDAC). Study design: This study is a prospective single-center phase II trial which aimed to examine whether a supervised exercise therapy for PDAC improved the completion rate of S-1 adjuvant chemotherapy for development of a tolerable and effective exercise plan for patients undergoing adjuvant therapy. Results: Forty-three patients were included in the study. The completion rate of S-1 therapy, the primary endpoint, was 93%, which exceeded the threshold completion rate of 53% (P P = 0.002) and significant increase in G8 questionnaire score (P < 0.001), indicating that exercise therapy reduced frailty. There were no incidences of serious adverse events except for one case of grade 3 febrile neutropenia. The differences between before/after therapy (between 6 months/baseline) of mean muscle mass, mean body fat mass, mean body fat percentage, and mean controlling nutrition status (CONUT) score were 1.52 (P < 0.001), -1.18 (P = 0.007), -2.47 (P < 0.001), and -0.59 (P = 0.006) respectively. Conclusions: Adjuvant chemotherapy combined with supervised exercise therapy for PDAC was confirmed to improve the completion rate of S-1 adjuvant chemotherapy.

This publication has 31 references indexed in Scilit: